M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The purpose of this first-in-human study is to identify a recommend dose(s) for subsequent larger studies (recommended dose(s) for expansion, RDE), examining increasing doses of M0324, primarily looking at safety, but also preliminary signs of efficacy, pharmacokinetics (PK), and pharmacodynamics (PD). Three different treatments with M0324 will be studied, M0324 as a monotherapy(Part 1), M0324 in combination with pembrolizumab (Part 2), and in combination with mFOLFIRINOX (a chemotherapy treatment)(Part 3).
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Część 1: Zaawansowany nowotwór, który nie odpowiada na standardowe leczenie lub pacjent go nie toleruje
- •Część 2: Zaawansowany nowotwór, pacjent wcześniej otrzymywał immunoterapię, ale choroba się pogorszyła
- •Część 3: Nieoperowany rak trzustki przydatny do leczenia chemioterapią mFOLFIRINOX
✗ Disqualifies
- •Przewlekła biegunka lub choroby zapalne jelita grubego
- •Historia innego nowotworu złośliwego w ciągu ostatnich 3 lat
- •Nieskontrolowane wysokie ciśnienie tętnicze, poważne problemy z sercem lub zawał w ostatnich 6 miesiącach
- •Spodziewana długość przeżycia poniżej 3 miesięcy
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 17, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (5)
Yale University School of Medicine
New Haven, United States
Icahn School of Medicine at Mount Sinai
New York, United States
NEXT Oncology
San Antonio, United States
Princess Margaret Cancer Centre
Toronto, Canada
National Cancer Center Hospital
Chūōku, Japan
Trial contact
US Medical Information
Communication Center
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/18/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.